Seltorexant


Seltorexant is a selective, small-molecule antagonist of the OX2 receptor that is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceutica for the treatment of insomnia and major depressive disorder. As of December 2015, it is in phase II clinical trials for both insomnia and Major depressive disorder.